Research

Research2019-07-15T20:43:36+00:00
Target identification and validation
Drug discovery and development
Clinical science and correlatives

Target identification and validation

Leverage our technologies to identify and validate potential drug targets:

  • CRISPR/Cas9
  • scRNAseq
  • Flow- and CyTOF-based immune profiling
  • Organotypic spheroids

Our target identification efforts feed directly into our partners’ drug discovery efforts, fueling preclinical development pathways.

Related publications
Screening assay identifies new immunotherapy targets
www.ncbi.nlm.nih.gov/pubmed/30242021

3D microfluidic device models tumor microenvironment
www.ncbi.nlm.nih.gov/pubmed/29101162

Drug discovery and development

Our efforts focus on drug evaluation, responder ID, and biomarker discovery to IND submission:

  • In vitro & in vivo pharmacology
  • Patient-derived xenograft (PDX)
  • Syngeneic models of cancer

Our strategic alliances

  • AstraZeneca: Collaboration to address drug-resistant lung cancer
  • Janssen: Collaboration to assess next-generation immunotherapies
  • Daiichi Sankyo: Collaboration to develop novel targeted therapies for lung cancer

Clinical science and correlatives

We accelerate clinical research:

  • Liquid biopsy to augment precision medicine
  • Immune profiling to characterize patients treated with checkpoint blockade

Related publications
Defining inflammatory microenvironment in head & neck cancer
www.ncbi.nlm.nih.gov/pubmed/28351582

“Hot” and “cold” immunophenotypes identified in lung cancer
www.ncbi.nlm.nih.gov/pubmed/27699239

Plasma NGS panel developed to identify targetable NSCLC mutations
www.ncbi.nlm.nih.gov/pubmed/26459174